Harvard Bioscience, Inc. (HBIO) |
| 0.6137 0.013 (2.13%) 02-27 16:00 |
| Open: | 0.59 |
| High: | 0.639 |
| Low: | 0.59 |
| Volume: | 260,287 |
| Market Cap: | 27(M) |
| PE Ratio: | -0.51 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 0.76 |
| Resistance 1: | 0.65 |
| Pivot price: | 0.57 |
| Support 1: | 0.54 |
| Support 2: | 0.47 |
| 52w High: | 0.95 |
| 52w Low: | 0.28 |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
| EPS | -1.210 |
| Book Value | 0.320 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.113 |
| Profit Margin (%) | -61.62 |
| Operating Margin (%) | 1.19 |
| Return on Assets (ttm) | -0.8 |
| Return on Equity (ttm) | -135.6 |
Thu, 26 Feb 2026
Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET - The Manila Times
Tue, 10 Feb 2026
Harvard Bioscience Reports Preliminary Q4 Results and Outlines Growth Strategy for 2026 - Quiver Quantitative
Fri, 30 Jan 2026
What's Going On With Harvard Bioscience Stock Friday? - Harvard Bioscience (NASDAQ:HBIO) - Benzinga
Mon, 22 Dec 2025
Harvard Bioscience Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Wed, 17 Dec 2025
Life science tools firm lands $40M boost and adds veteran investor - Stock Titan
Wed, 17 Dec 2025
Harvard Bioscience Announces the Successful Completion of - GlobeNewswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |